Baird Medical Engages Global Clinical Leaders at AAES 2025
Baird Medical (NASDAQ: BDMD) participated in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES) from May 17-19, 2025, in Milwaukee, Wisconsin. The company, specializing in Microwave Ablation (MWA) technology, showcased its innovative MWA system for thyroid nodule treatment at the event.
The presentation highlighted the system's advantages as a minimally invasive alternative to traditional surgery, including reduced procedural risks, preserved thyroid function, and faster recovery times. The company engaged with attending surgeons to gather feedback on practical aspects such as patient selection, ultrasound guidance optimization, and various application scenarios.
Baird Medical (NASDAQ: BDMD) ha partecipato al 45° Congresso Annuale della American Association of Endocrine Surgeons (AAES), tenutosi dal 17 al 19 maggio 2025 a Milwaukee, Wisconsin. L'azienda, specializzata nella tecnologia di Ablazione a Microonde (MWA), ha presentato il suo innovativo sistema MWA per il trattamento dei noduli tiroidei durante l'evento.
La presentazione ha evidenziato i vantaggi del sistema come alternativa minimamente invasiva alla chirurgia tradizionale, tra cui la riduzione dei rischi procedurali, la conservazione della funzione tiroidea e tempi di recupero più rapidi. L'azienda ha interagito con i chirurghi presenti per raccogliere feedback su aspetti pratici come la selezione dei pazienti, l'ottimizzazione della guida ecografica e i diversi scenari di applicazione.
Baird Medical (NASDAQ: BDMD) participó en la 45ª Reunión Anual de la American Association of Endocrine Surgeons (AAES) del 17 al 19 de mayo de 2025 en Milwaukee, Wisconsin. La empresa, especializada en la tecnología de Ablación por Microondas (MWA), presentó su innovador sistema MWA para el tratamiento de nódulos tiroideos en el evento.
La presentación destacó las ventajas del sistema como una alternativa mínimamente invasiva a la cirugía tradicional, incluyendo la reducción de riesgos del procedimiento, la preservación de la función tiroidea y tiempos de recuperación más rápidos. La empresa interactuó con los cirujanos asistentes para recopilar opiniones sobre aspectos prácticos como la selección de pacientes, la optimización de la guía por ultrasonido y los distintos escenarios de aplicación.
Baird Medical (NASDAQ: BDMD)는 2025년 5월 17일부터 19일까지 위스콘신주 밀워키에서 열린 제45회 미국 내분비외과학회(AAES) 연례회의에 참가했습니다. 마이크로웨이브 절제술(MWA) 기술을 전문으로 하는 이 회사는 갑상선 결절 치료를 위한 혁신적인 MWA 시스템을 행사에서 선보였습니다.
발표에서는 전통적인 수술에 비해 최소 침습적 대안으로서 절차 위험 감소, 갑상선 기능 보존, 빠른 회복 시간 등의 시스템 장점을 강조했습니다. 회사는 참석한 외과의들과 환자 선정, 초음파 유도 최적화, 다양한 적용 시나리오 등 실용적인 측면에 대해 의견을 교환했습니다.
Baird Medical (NASDAQ : BDMD) a participé à la 45e réunion annuelle de l'American Association of Endocrine Surgeons (AAES) du 17 au 19 mai 2025 à Milwaukee, Wisconsin. L'entreprise, spécialisée dans la technologie d'ablation par micro-ondes (MWA), a présenté son système MWA innovant pour le traitement des nodules thyroïdiens lors de l'événement.
La présentation a mis en avant les avantages du système en tant qu'alternative peu invasive à la chirurgie traditionnelle, notamment la réduction des risques liés à la procédure, la préservation de la fonction thyroïdienne et des temps de récupération plus rapides. L'entreprise a échangé avec les chirurgiens présents afin de recueillir leurs retours sur des aspects pratiques tels que la sélection des patients, l'optimisation de la guidage par échographie et les différents scénarios d'application.
Baird Medical (NASDAQ: BDMD) nahm an der 45. Jahrestagung der American Association of Endocrine Surgeons (AAES) vom 17. bis 19. Mai 2025 in Milwaukee, Wisconsin, teil. Das Unternehmen, spezialisiert auf Microwellenablation (MWA)-Technologie, präsentierte auf der Veranstaltung sein innovatives MWA-System zur Behandlung von Schilddrüsenknoten.
Die Präsentation hob die Vorteile des Systems als minimalinvasive Alternative zur traditionellen Chirurgie hervor, darunter reduzierte Verfahrensrisiken, Erhalt der Schilddrüsenfunktion und schnellere Erholungszeiten. Das Unternehmen tauschte sich mit den anwesenden Chirurgen aus, um Feedback zu praktischen Aspekten wie Patientenauswahl, Optimierung der Ultraschallführung und verschiedenen Anwendungsszenarien zu erhalten.
- None.
- None.
The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine surgery. For Baird Medical, this event is a key platform to showcase its latest MWA technological achievements and to foster direct engagement with healthcare professionals, thereby gaining deeper insights into the evolving needs of the medical community.
At this year's meeting, Baird Medical presented its pioneering MWA system for thyroid nodule treatment, emphasizing its benefits as a minimally invasive alternative to conventional surgery. The technology garnered considerable interest from attending surgeons, who recognized its potential to enhance patient outcomes by minimizing procedural risks, preserving thyroid function, and expediting recovery. Through substantive dialogues with clinical experts, Baird Medical acquired critical feedback on practical aspects including patient selection, ultrasound guidance optimization, and diverse application scenarios.
The insights and perspectives gathered at AAES 2025 are pivotal for shaping Baird Medical's future clinical collaboration initiatives. By maintaining a close alignment with the requirements of surgeons and their patients, the Company remains committed to advancing its mission of delivering safer, more effective treatment solutions for thyroid and other endocrine diseases.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-engages-global-clinical-leaders-at-aaes-2025-302458639.html
SOURCE BDMD
FAQ
What did Baird Medical (BDMD) present at AAES 2025?
What are the key benefits of Baird Medical's MWA system for thyroid treatment?
When and where was the AAES 2025 Annual Meeting held?
What feedback did Baird Medical receive at AAES 2025?
